G Sachs Provides ST Risk Assessment for Three Firm Types as US Expected to Increase Scrutiny on CN Innovative Drugs, Potentially Creating 'Headline Risks' for CN Pharmaceutical Companies
Trump Administration's Drug Policy Discussion: Goldman Sachs reported that the Trump administration is considering restrictions on Chinese pharmaceuticals and drafting an executive order to limit the entry of innovative Chinese drugs into the US market, although a White House spokesperson stated that the government is not actively pursuing this draft at the moment.
Impact on Chinese Biotech Sector: Goldman Sachs believes that potential restrictions could create "headline risks" for the Chinese biotech and pharmaceutical sector, leading to increased stock price volatility, especially as major US pharmaceutical companies lobby against the proposed order.
Categorization of Chinese Biotech Companies: The report categorizes Chinese biotech firms into three groups based on their global presence and partnerships, with varying levels of expected impact from the potential restrictions.
Market Reactions and Short Selling Data: The article includes specific stock performance and short selling data for various companies within the categorized groups, indicating market sentiment and potential risks associated with the evolving regulatory landscape.
Trade with 70% Backtested Accuracy
Analyst Views on 01093
About the author
Midday Update: HSI Ends at 26,724, Down 109 Points; HSTI at 5,347, Down 119 Points; TENCENT Falls Over 3%; XINYI GLASS, TECHTRONIC IND, WHARF REIC, YANKUANG ENERGY, and CHINA EAST AIR Reach New Highs
Market Performance: The HSI dropped 109 points (0.4%) to 26,724, while the HSTI fell 119 points (2.2%) to 5,347, and the HSCEI decreased by 48 points (0.5%) to 9,004.
Active Heavyweights: Major stocks like TENCENT, XIAOMI, and MEITUAN saw declines, with TENCENT down 3.4% and XIAOMI down 2.6%, while BABA fell 0.9%.
Notable Movers: XINYI GLASS and CHINA SHENHUA experienced significant gains, with XINYI GLASS up 6.2% and CHINA SHENHUA up 5.4%, while TRIP.COM-S dropped 6.1%.
Short Selling Trends: High short selling ratios were observed in several stocks, including XIAOMI (20.155%) and MEITUAN (17.261%), indicating increased bearish sentiment among investors.
<Daily Summary> HSI Ends at 26,834, Gaining 59 Points; HSTI Finishes at 5,467, Losing 59 Points; CSPC PHARMA Surges Over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Reach New Peaks; Market Turnover Increases
Market Performance: The HSI rose by 59 points (0.2%) to 26,834, while the HSTI and HSCEI fell by 59 points (1.1%) and 27 points (0.3%) respectively, with a total market turnover of $335.15 billion.
Active Heavyweights: Major stocks like Tencent, Meituan, and Alibaba saw declines, with Tencent closing down 2.9% at $581, while Ping An was the only heavyweight to gain, closing up 0.8% at $71.3.
Notable Movers: CSPC Pharma and New Oriental experienced significant gains, rising 8.1% and 6.4% respectively, while Kuaishou-W and Baidu-SW faced notable declines, down 4.6% and 3.6%.
High Performers: CIMC and Wanguo Gold GP were standout performers, with CIMC surging 15% and Wanguo Gold GP increasing by 13.6%, both hitting new highs.
<Midday Update> HSI Ends Midday at 26,830, Gaining 54 Points; HSTI Ends Midday at 5,453, Losing 72 Points; TENCENT Falls More Than 3%; MTR CORPORATION, POWER ASSETS, CIMC, ZOOMLION, FIH Reach New Peaks
Market Performance: The HSI rose by 54 points (0.2%) to 26,830, while the HSTI and HSCEI fell by 72 points (1.3%) and 19 points (0.2%) respectively.
Active Heavyweights: Major stocks like Tencent, Alibaba, and Meituan experienced declines, with Tencent down 4.0% and Alibaba down 2.3%, while Ping An saw a slight increase of 0.9%.
Notable Movers: CSPC Pharma and CKH Holdings saw significant gains, up 3.5% and 3.4% respectively, while Kuaishou-W dropped 5.1%.
High Performers: Stocks like Fangzhou Jianke and CIMC achieved notable increases of 15.3% and 16.1%, reaching new highs in their respective performances.
CICC Increases CSPC PHARMA (01093.HK) Price Target to $12, Expects Ongoing Out-licensing Success
CSPC Pharma Collaboration: CSPC Pharma has authorized AstraZeneca to exclusively develop and commercialize eight innovative long-acting peptide medicine projects globally, with AstraZeneca set to pay $1.2 billion upfront and potential milestone payments totaling up to $17.3 billion.
Market Performance: CSPC Pharma's stock has seen a decline of 3.333%, with short selling amounting to $111.61 million and a ratio of 8.919%.
Research and Development Pipeline: The company is advancing its R&D pipeline with innovative assets like the EGF RADC/SiRNA series and expects continued out-licensing and milestone revenue recognition.
Earnings Forecast and Target Price: CICC has maintained its earnings forecasts for 2025 and 2026 while introducing a new forecast for 2027, raising the target price by 9.1% to $12, while keeping the rating at Outperform.
BofAS Sets CSPC PHARMA (01093.HK) Target Price at $9.1, Maintains Underperform Rating Due to Sales Challenges
CSPC Pharma Agreement: CSPC Pharma has entered into a partnership with AstraZeneca to develop long-acting peptide medicines, with the agreement potentially valued at up to $18.5 billion.
Financial Details: The deal includes an upfront payment of $1.2 billion, with additional potential payments of up to $3.5 billion for R&D milestones and $13.8 billion for sales milestones.
Market Reaction: Following the announcement, BofA Securities raised CSPC's target price from $8.5 to $9.1 but maintained an "Underperform" rating due to anticipated sales pressure on existing products and limited short-term contributions from the R&D pipeline.
Short Selling Information: CSPC Pharma is experiencing significant short selling, with a total of $1.27 billion and a short selling ratio of 22.865%.
CSPC PHARMA Sees HKD934.6M Net Inflow from Southbound Trading
Southbound Trading Inflows: CSPC PHARMA (01093.HK) saw a significant net inflow of HKD934.6 million, while ZIJIN MINING (02899.HK) experienced a net outflow of HKD635.5 million in Southbound Trading.
Short Selling Activity: CSPC PHARMA had a short selling amount of $1.27 billion with a ratio of 22.865%, while ZIJIN MINING reported $1.03 billion in short selling with a ratio of 13.018%.
Most Active Stocks: In the Shanghai-Hong Kong Stock Connect, CSPC PHARMA was the most active stock with the highest net inflow, while CNOOC (00883.HK) had the highest net outflow. In the Shenzhen-Hong Kong Stock Connect, TRACKER FUND (02800.HK) led in inflows, and ZIJIN MINING led in outflows.
Overall Trading Summary: The total Southbound Trading net outflow was HKD0, accounting for 38.62% of the total transaction amount of HKD116.49 billion.
Midday Update: HSI Ends at 26,724, Down 109 Points; HSTI at 5,347, Down 119 Points; TENCENT Falls Over 3%; XINYI GLASS, TECHTRONIC IND, WHARF REIC, YANKUANG ENERGY, and CHINA EAST AIR Reach New Highs
Market Performance: The HSI dropped 109 points (0.4%) to 26,724, while the HSTI fell 119 points (2.2%) to 5,347, and the HSCEI decreased by 48 points (0.5%) to 9,004.
Active Heavyweights: Major stocks like TENCENT, XIAOMI, and MEITUAN saw declines, with TENCENT down 3.4% and XIAOMI down 2.6%, while BABA fell 0.9%.
Notable Movers: XINYI GLASS and CHINA SHENHUA experienced significant gains, with XINYI GLASS up 6.2% and CHINA SHENHUA up 5.4%, while TRIP.COM-S dropped 6.1%.
Short Selling Trends: High short selling ratios were observed in several stocks, including XIAOMI (20.155%) and MEITUAN (17.261%), indicating increased bearish sentiment among investors.
<Daily Summary> HSI Ends at 26,834, Gaining 59 Points; HSTI Finishes at 5,467, Losing 59 Points; CSPC PHARMA Surges Over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Reach New Peaks; Market Turnover Increases
Market Performance: The HSI rose by 59 points (0.2%) to 26,834, while the HSTI and HSCEI fell by 59 points (1.1%) and 27 points (0.3%) respectively, with a total market turnover of $335.15 billion.
Active Heavyweights: Major stocks like Tencent, Meituan, and Alibaba saw declines, with Tencent closing down 2.9% at $581, while Ping An was the only heavyweight to gain, closing up 0.8% at $71.3.
Notable Movers: CSPC Pharma and New Oriental experienced significant gains, rising 8.1% and 6.4% respectively, while Kuaishou-W and Baidu-SW faced notable declines, down 4.6% and 3.6%.
High Performers: CIMC and Wanguo Gold GP were standout performers, with CIMC surging 15% and Wanguo Gold GP increasing by 13.6%, both hitting new highs.
<Midday Update> HSI Ends Midday at 26,830, Gaining 54 Points; HSTI Ends Midday at 5,453, Losing 72 Points; TENCENT Falls More Than 3%; MTR CORPORATION, POWER ASSETS, CIMC, ZOOMLION, FIH Reach New Peaks
Market Performance: The HSI rose by 54 points (0.2%) to 26,830, while the HSTI and HSCEI fell by 72 points (1.3%) and 19 points (0.2%) respectively.
Active Heavyweights: Major stocks like Tencent, Alibaba, and Meituan experienced declines, with Tencent down 4.0% and Alibaba down 2.3%, while Ping An saw a slight increase of 0.9%.
Notable Movers: CSPC Pharma and CKH Holdings saw significant gains, up 3.5% and 3.4% respectively, while Kuaishou-W dropped 5.1%.
High Performers: Stocks like Fangzhou Jianke and CIMC achieved notable increases of 15.3% and 16.1%, reaching new highs in their respective performances.
CICC Increases CSPC PHARMA (01093.HK) Price Target to $12, Expects Ongoing Out-licensing Success
CSPC Pharma Collaboration: CSPC Pharma has authorized AstraZeneca to exclusively develop and commercialize eight innovative long-acting peptide medicine projects globally, with AstraZeneca set to pay $1.2 billion upfront and potential milestone payments totaling up to $17.3 billion.
Market Performance: CSPC Pharma's stock has seen a decline of 3.333%, with short selling amounting to $111.61 million and a ratio of 8.919%.
Research and Development Pipeline: The company is advancing its R&D pipeline with innovative assets like the EGF RADC/SiRNA series and expects continued out-licensing and milestone revenue recognition.
Earnings Forecast and Target Price: CICC has maintained its earnings forecasts for 2025 and 2026 while introducing a new forecast for 2027, raising the target price by 9.1% to $12, while keeping the rating at Outperform.
BofAS Sets CSPC PHARMA (01093.HK) Target Price at $9.1, Maintains Underperform Rating Due to Sales Challenges
CSPC Pharma Agreement: CSPC Pharma has entered into a partnership with AstraZeneca to develop long-acting peptide medicines, with the agreement potentially valued at up to $18.5 billion.
Financial Details: The deal includes an upfront payment of $1.2 billion, with additional potential payments of up to $3.5 billion for R&D milestones and $13.8 billion for sales milestones.
Market Reaction: Following the announcement, BofA Securities raised CSPC's target price from $8.5 to $9.1 but maintained an "Underperform" rating due to anticipated sales pressure on existing products and limited short-term contributions from the R&D pipeline.
Short Selling Information: CSPC Pharma is experiencing significant short selling, with a total of $1.27 billion and a short selling ratio of 22.865%.
CSPC PHARMA Sees HKD934.6M Net Inflow from Southbound Trading
Southbound Trading Inflows: CSPC PHARMA (01093.HK) saw a significant net inflow of HKD934.6 million, while ZIJIN MINING (02899.HK) experienced a net outflow of HKD635.5 million in Southbound Trading.
Short Selling Activity: CSPC PHARMA had a short selling amount of $1.27 billion with a ratio of 22.865%, while ZIJIN MINING reported $1.03 billion in short selling with a ratio of 13.018%.
Most Active Stocks: In the Shanghai-Hong Kong Stock Connect, CSPC PHARMA was the most active stock with the highest net inflow, while CNOOC (00883.HK) had the highest net outflow. In the Shenzhen-Hong Kong Stock Connect, TRACKER FUND (02800.HK) led in inflows, and ZIJIN MINING led in outflows.
Overall Trading Summary: The total Southbound Trading net outflow was HKD0, accounting for 38.62% of the total transaction amount of HKD116.49 billion.
